INTRODUCTION: Determinants of erectile dysfunction in diabetic men have not been adequately investigated as potential mediators of change. AIM: To determine the prevalence and correlates of erectile dysfunction (ED) in overweight men with type 2 diabetes in the multicenter, Look AHEAD trial (Action for Health in Diabetes). MAIN OUTCOME MEASURES: International Index of Erectile Function (IIEF), self-reported use of phosphodiesterase type 5 inhibitors, laboratory measures of adiposity, cardiometabolic parameters, and exercise fitness. METHODS:Male participants aged 45-75 in the Look AHEAD trial in a committed relationship were recruited for an ongoing study of sexual function and diabetes. Eligible participants completed the IIEF questionnaire and provided updated information on use of medical treatments for sexual dysfunction. Baseline sexual function results for participants in the male ancillary study are reported here; intervention data and results for female participants are presented elsewhere. RESULTS: A total of 373 eligible male participants completed all sexual function questionnaires, of whom 263 (68.7%) were sexually active at the time of the study. Almost half (49.8%) of the men reported mild or moderate degrees of ED, and 24.8% had complete ED. Among sexually active participants, 42.6% had sought medical help for their problem, and 39.7% reported use of ED medications. ED was significantly associated with age (odds ratio [OR] = 1.05; confidence interval [CI]: 1.01-1.10) baseline HbA(1c) (OR = 1.31; CI: 1.05-1.63), hypertension history (OR = 2.41; CI: 1.34-4.36), and metabolic syndrome (OR = 3.05, CI: 1.31-7.11). Of note, cardiorespiratory fitness was found to be protective of ED in a multivariable analysis (OR = 0.61; P < 0.001). CONCLUSIONS: ED is prevalent in this sample of obese, type 2 diabetic men in the Look AHEAD study. Cardiovascular risk factors were highly associated with ED in this population, and cardiorespiratory fitness was protective in this analysis.
RCT Entities:
INTRODUCTION: Determinants of erectile dysfunction in diabeticmen have not been adequately investigated as potential mediators of change. AIM: To determine the prevalence and correlates of erectile dysfunction (ED) in overweight men with type 2 diabetes in the multicenter, Look AHEAD trial (Action for Health in Diabetes). MAIN OUTCOME MEASURES: International Index of Erectile Function (IIEF), self-reported use of phosphodiesterase type 5 inhibitors, laboratory measures of adiposity, cardiometabolic parameters, and exercise fitness. METHODS: Male participants aged 45-75 in the Look AHEAD trial in a committed relationship were recruited for an ongoing study of sexual function and diabetes. Eligible participants completed the IIEF questionnaire and provided updated information on use of medical treatments for sexual dysfunction. Baseline sexual function results for participants in the male ancillary study are reported here; intervention data and results for female participants are presented elsewhere. RESULTS: A total of 373 eligible male participants completed all sexual function questionnaires, of whom 263 (68.7%) were sexually active at the time of the study. Almost half (49.8%) of the men reported mild or moderate degrees of ED, and 24.8% had complete ED. Among sexually active participants, 42.6% had sought medical help for their problem, and 39.7% reported use of ED medications. ED was significantly associated with age (odds ratio [OR] = 1.05; confidence interval [CI]: 1.01-1.10) baseline HbA(1c) (OR = 1.31; CI: 1.05-1.63), hypertension history (OR = 2.41; CI: 1.34-4.36), and metabolic syndrome (OR = 3.05, CI: 1.31-7.11). Of note, cardiorespiratory fitness was found to be protective of ED in a multivariable analysis (OR = 0.61; P < 0.001). CONCLUSIONS: ED is prevalent in this sample of obese, type 2 diabeticmen in the Look AHEAD study. Cardiovascular risk factors were highly associated with ED in this population, and cardiorespiratory fitness was protective in this analysis.
Authors: Steven A Grover; Ilka Lowensteyn; Mohammed Kaouache; Sylvie Marchand; Louis Coupal; Emidio DeCarolis; Joseph Zoccoli; Isabelle Defoy Journal: Arch Intern Med Date: 2006-01-23
Authors: Ian M Thompson; Catherine M Tangen; Phyllis J Goodman; Jeffrey L Probstfield; Carol M Moinpour; Charles A Coltman Journal: JAMA Date: 2005-12-21 Impact factor: 56.272
Authors: George Bray; Edward Gregg; Steven Haffner; Xavier F Pi-Sunyer; Lynne E WagenKnecht; Michael Walkup; Rena Wing Journal: Diab Vasc Dis Res Date: 2006-12 Impact factor: 3.291
Authors: Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski Journal: Control Clin Trials Date: 2003-10
Authors: Paul M Ribisl; Wei Lang; Sarah A Jaramillo; John M Jakicic; Kerry J Stewart; Judy Bahnson; Renee Bright; Jeff F Curtis; Richard S Crow; Judith E Soberman Journal: Diabetes Care Date: 2007-07-20 Impact factor: 19.112
Authors: David B Sarwer; Jacqueline C Spitzer; Thomas A Wadden; Raymond C Rosen; James E Mitchell; Kathy Lancaster; Anita Courcoulas; William Gourash; Nicholas J Christian Journal: Surg Obes Relat Dis Date: 2013-07-12 Impact factor: 4.734
Authors: Aruna V Sarma; James M Hotaling; Ian H de Boer; Rodney L Dunn; Mary K Oerline; Karandeep Singh; Jack Goldberg; Alan Jacobson; Barbara Braffett; William H Herman; Rodica Pop-Busui; Hunter Wessells Journal: J Hypertens Date: 2019-05 Impact factor: 4.844
Authors: Rena R Wing; Raymond C Rosen; Joseph L Fava; Judy Bahnson; Frederick Brancati; Isaias Noel C Gendrano Iii; Abbas Kitabchi; Stephen H Schneider; Thomas A Wadden Journal: J Sex Med Date: 2009-08-17 Impact factor: 3.802